Clinical efficacy and safety of ceftobiprole in the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials

References

• Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15(9):1516–1518.
   PubMed Web of Science ®Google Scholar
• Mistry RD. Skin and Soft Tissue Infections in ambulatory care settings: setting a new trend. Clin Infect Dis. 2020;70(12):2719–2720.
   PubMed Web of Science ®Google Scholar
• Hersh AL, Chambers HF, Maselli JH, et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168(14):1585–1591.
   PubMed Web of Science ®Google Scholar
• Storandt MH, Walden CD, Sahmoun AE, et al. Trends and risk factors in the antibiotic management of skin and soft tissue infections in the United States. J Dermatolog Treat. 2021;1–15. DOI: https://doi.org/10.1080/09546634.2020.1859442.
   Google Scholar
• Breyre A, Frazee BW. Skin and soft tissue infections in the emergency department. Emerg Med Clin North Am. 2018;36(4):723–750.
   PubMed Web of Science ®Google Scholar
• Fritz SA, Shapiro DJ, Hersh AL. National trends in incidence of purulent skin and soft tissue infections in patients presenting to ambulatory and emergency department settings, 2000-2015. Clin Infect Dis. 2020;70(12):2715–2718.
   PubMed Web of Science ®Google Scholar
• Hatlen TJ, Miller LG. 2020. Staphylococcal skin and soft tissue Infections. Infect Dis Clin North Am. 1. DOI: https://doi.org/10.1016/j.idc.2020.10.003.
   Google Scholar
• Jabbour JF, Kanj SS. Gram-negative skin and soft tissue infections. Infect Dis Clin North Am. 2021;35(1):157–167.
   PubMed Web of Science ®Google Scholar
• Tirupathi R, Areti S, Salim SA, et al. Acute bacterial skin and soft tissue infections: new drugs in ID armamentarium. J Community Hosp Intern Med Perspect. 2019;9(4):310–313.
   PubMed Web of Science ®Google Scholar
• Lan SH, Chang SP, Lai CC, et al. The efficacy and safety of omadacycline in treatment of acute bacterial infection: a systemic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98(51):e18426.
   PubMed Web of Science ®Google Scholar
• Lan SH, Lai CC, Lu LC, et al. Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019;12:1415–1423.
   PubMed Web of Science ®Google Scholar
• Lan SH, Chang SP, Lai CC, et al. Ceftaroline efficacy and safety in treatment of complicated skin and soft tissue infection: a systemic review and meta-analysis of randomized controlled trials. J Clin Med. 2019;8(6):776.
   PubMed Web of Science ®Google Scholar
• Lan SH, Lin WT, Chang SP, et al. Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis. Antibiotics (Basel). 2019;8(3):137.
   Web of Science ®Google Scholar
• Barbour A, Schmidt S, Rand KH, et al. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2009;34(1):1–7.
   PubMed Web of Science ®Google Scholar
• Bogdanovich T, Ednie LM, Shapiro S, et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 2005;49(10):4210–4219.
   PubMed Web of Science ®Google Scholar
• Deitchman A, De Jong D, Barbour A, et al. Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections. Expert Rev Anti Infect Ther. 2016;14(11):997–1006.
   PubMed Web of Science ®Google Scholar
• Del Pozo JL, Patel R. Ceftobiprole medocaril: a new generation beta-lactam. Drugs Today (Barc). 2008;44(11):801–825.
   PubMed Web of Science ®Google Scholar
• Falcó V, Burgos J, Almirante B. Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018;19(13):1503–1509.
   PubMed Web of Science ®Google Scholar
• Flamm RK, Duncan LR, Hamed KA, et al. Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018. Antimicrob Agents Chemother. 2020;64(6):6.
   Web of Science ®Google Scholar
• Pfaller MA, Flamm RK, Duncan LR, et al. Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017). Diagn Microbiol Infect Dis. 2019;94(3):304–313.
   PubMed Web of Science ®Google Scholar
• Stucki A, Cottagnoud M, Acosta F, et al. Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model. Antimicrob Agents Chemother. 2012;56(2):921–925.
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59(1):51–61.
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Welte T, File TM Jr., et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39(3):240–246.
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46(5):647–655.
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008;52(1):37–44.
   PubMed Web of Science ®Google Scholar
• Overcash JS, Kim C, Keech R, et al. Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET). Clin Infect Dis. 2020 Sep 8. DOI:https://doi.org/10.1093/cid/ciaa974. [ ciaa974].
   Web of Science ®Google Scholar
• Eljaaly K, Wali H, Basilim A, et al. Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis. Int J Antimicrob Agents. 2019;54(2):149–153.
   PubMed Web of Science ®Google Scholar
• Pooley N, Chadda S, Madrigal AM, et al. A network meta-analysis comparing the efficacy and safety of ceftobiprole and selected comparators in the treatment of hospital-acquired pneumonia. Value Health. 2014;17(7):A588.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103–112.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928.
   PubMed Web of Science ®Google Scholar
• Amsler KM, Davies TA, Shang W, et al. In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2008;52(9):3418–3423.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Flamm RK, Mendes RE, et al. Ceftobiprole activity against Gram-positive and -negative Pathogens collected from the United States in 2006 and 2016. Antimicrob Agents Chemother. 2019;63(1):e01566–18.
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis. 2008;61(1):86–95.
   PubMed Web of Science ®Google Scholar
• Cereda RF, Azevedo HD, Girardello R, et al. Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study. Braz J Infect Dis. 2011;15(4):339–348.
   PubMed Web of Science ®Google Scholar